Table 1.
Baseline characteristics of the METAFIB-OA cohort
| Total (n=301) |
HIV-1 + MetS+ (n=152) |
HIV-1 + MetS− (n=149) |
p Value | |
|---|---|---|---|---|
|
| ||||
| Demographic features | ||||
|
| ||||
| Male gender, n (%) | 265 (88.0) | 134 (88.2) | 131 (87.9) | 0.9 |
|
| ||||
| Age (years), mean (SD) | 53.4 (5.0) | 53.5 (4.9) | 53.4 (5.1) | 0.7 |
|
| ||||
| Postmenopausal status (n=37), n (%) | 26 (70.3) | 14 (77.8) | 12 (63.2) | 0.5 |
|
| ||||
| Predominant side, n (%) | ||||
|
| ||||
| Right-handed | 250 (83.1) | 133 (87.5) | 117 (78.5) | |
|
| ||||
| Left-handed | 32 (10.6) | 13 (8.6) | 19 (12.8) | |
|
| ||||
| Mixed | 19 (6.3) | 6 (3.9) | 13 (8.7) | 0.1 |
|
| ||||
| Hand OA features | ||||
|
| ||||
| Hand trauma history, n (%) | 62 (20.6) | 26 (%) | 36 (%) | 0.2 |
|
| ||||
| Psoriasis, n (%) | 13 (4.3) | 4 (2.6) | 9 (6.0) | 0.2 |
|
| ||||
| Pain, n (%) | 80 (26.6) | 42 (27.6) | 38 (25.5) | 0.7 |
|
| ||||
| HIV features | ||||
|
| ||||
| Duration of HIV infection (years), mean (SD) | 17.7 (7.3) | 17.0 (7.1) | 18.3 (7.5) | 0.2 |
|
| ||||
| CDC-C stage, n (%) | 81 (26.9) | 43 (28.3) | 38 (25.5) | 0.8 |
|
| ||||
| CD4 level (/mm3), mean (SD) | 623 (265) | 625 (257) | 621 (274) | 0.9 |
|
| ||||
| CD4/CD8 ratio, mean (SD) | 0.87 (0.37) | 0.86 (0.4) | 0.87 (0.3) | 0.4 |
|
| ||||
| Undetectable usHIV viral load, n (%) | 240 (79.7) | 82 (53.9) | 90 (60.8) | 0.2 |
|
| ||||
| Duration of exposure to protease inhibitors (months), mean (SD) | 47.7 (29.2) | 26.9 (31.1) | 27.4 (33.6) | 0.8 |
|
| ||||
| Metabolic syndrome components | ||||
|
| ||||
| Waist circumference (cm), mean (SD) | 92.2 (10.8) | 98.2 (10.1) | 86.3 (8.1) | <0.0001 |
|
| ||||
| BMI (kg/m2), mean (SD) | 24.9 (5.8) | 26.4 (4.8) | 23.3 (6.3) | <0.0001 |
|
| ||||
| Obesity (BMI≥30), n (%) | 32 (10.6) | 26 (17.1) | 6 (4.0) | <0.0001 |
|
| ||||
| Hypertension, n (%) | 56 (18.6) | 40 (26.3) | 16 (10.7) | <0.0001 |
|
| ||||
| Triglycerides (mmol/L), mean (SD) | 1.95 (1.9) | 2.47 (1.7) | 1.42 (2.0) | <0.0001 |
|
| ||||
| HDL-cho (mmol/L), mean (SD) | 1.21 (0.4) | 1.05 (0.3) | 1.36 (0.4) | <0.0001 |
|
| ||||
| LDL-cho (mmol/L), mean (SD) | 2.9 (0.9) | 3.1 (0.8) | 2.8 (0.9) | 0.0003 |
|
| ||||
| Glycaemia (mmol/L), mean (SD) | 5.45 (1.08) | 5.85 (1.3) | 5.05 (0.64) | <0.0001 |
|
| ||||
| HOMA-IR score, mean (SD) | 2.42 (2.79) | 3.51 (3.50) | 1.31 (0.92) | <0.0001 |
|
| ||||
| Type 2 diabetes, n (%) | 65 (21.6) | 57 (37.5) | 8 (5.4) | <0.0001 |
Data are number (%) or mean (SD) for the total population, and number (%) and median (IQR) for cases and controls.
Hypertension was defined as systolic pressure ≥140 mm Hg and/or diastolic pressure ≥90 mm Hg. Diabetes was defined as glycaemia >6 mmol/L.
BMI, body mass index; CDC, Centers for Disease Control and Prevention; cho, cholesterol; HDL, high-density lipoprotein; HOMA-IR score, Homeostasis Model Assessment of Insulin Resistance; LDL, low-density lipoprotein; METAFIB, Metabolic Syndrome and Fibrosis; MetS−, absence of metabolic syndrome; MetS, metabolic syndrome; MetS+, presence of metabolic syndrome; OA, osteoarthritis; usHIV: ultrasensitive HIV.